Bromantane

The short version: bromantane is a Russian "actoprotector" that boosts physical and mental performance without the crash of a stimulant, but the evidence base is thin, old, and mostly animal or review-level.

Bromantane (sold as Ladasten in Russia) is an adamantane derivative, a class that includes the antiviral amantadine [2]. It is classified as an actoprotector: a drug that increases endurance against physical loads without raising oxygen consumption or heat production, unlike classic stimulants [2]. The claimed effects are a combined stimulant and anti-anxiety action, improved attention, and immune modulation, with minimal withdrawal or overstimulation [2].

The mechanistic evidence comes from a 2007 rat study. Ladasten increased dopamine synthesis in brain regions tied to reward and memory, and converted short-term synaptic potentiation into long-term potentiation in hippocampal slices, an effect blocked by a dopamine receptor antagonist and by a protein synthesis inhibitor [1]. That suggests a real dopaminergic mechanism for the cognitive and motivational claims [1].

But the human evidence is essentially absent from this retrieval. The 2012 review describes clinical applications and says bromantane has no serious side effects, but it does not report a single controlled human trial with hard outcomes [2]. No long-term safety data appears anywhere in these records. No comparison against untreated controls in humans was retrieved.

What this means for you: if you are considering bromantane for fatigue, focus, or athletic performance, the plausibility is real but the proof is not. The animal mechanism is coherent [1], the class concept is documented [2], and the safety profile is described as benign [2], but "described as benign" is not the same as "proven safe in humans over years."

My call: the evidence is not clear. Bromantane has a plausible mechanism and a clean short-term profile in reviews, but no retrieved human trial with hard endpoints and no long-term safety data. Treat it as experimental. Confidence: low.